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Abstract 
Our recent studies of the microRNA (miRNA) expression signature in PCa 
indicated that miRNA-218 (miR-218) was significantly downregulated in clinical 
specimens, suggesting that miR-218 might act as a tumor-suppressive miRNA in 
PCa. The aim of this study was to investigate the functional significance of miR-218 
in PCa and to identify novel miR-218-regulated cancer pathways and target genes 
involved in PCa oncogenesis and metastasis. Restoration of miR-218 in PCa cell 
lines (PC3 and DU145) revealed that this miRNA significantly inhibited cancer cell 
migration and invasion. Gene expression data and in silico analysis demonstrated 
that LIM and SH3 protein 1 (LASP1) was a potential target of miR-218 regulation. 
LASP1 is a cytoskeletal scaffold protein that plays critical roles in cytoskeletal 
organization and cell migration.  Luciferase reporter assays showed that miR-218 
directly regulated expression of LASP1. Moreover, downregulating the LASP1 gene 
significantly inhibited cell migration and invasion in cancer cells, and the 
expression of LASP1 was upregulated in cancer tissues. We conclude that loss of 
tumor-suppressive miR-218 enhanced cancer cell migration and invasion in PCa 
through direct regulation of LASP1. Our data on pathways regulated by 
tumor-suppressive miR-218 provide new insights into the potential mechanisms of 
PCa oncogenesis and metastasis. 
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Introduction 
Prostate cancer (PCa) is the most frequently diagnosed cancer and the second 
leading cause of cancer death among men in developed countries.(1) Most patients 
are initially responsive to androgen-deprivation therapy (ADT), but their cancers 
eventually become resistant to ADT and progress to castration-resistant prostate 
cancer (CRPC). CRPC is difficult to treat, and most clinical trials for advanced PCa 
have shown limited benefits, with disease progression and metastasis to the 
skeleton or other sites.(2,3) Therefore, understanding the molecular mechanisms of 
CRPC and the metastatic pathways underlying PCa using genomic approaches 
would help to improve therapies for and prevention of the disease. 
The discovery of non-coding RNAs (ncRNAs) in the human genome was an 
important conceptual breakthrough in the post-genome sequencing era.(4) Improved 
understanding of ncRNAs is necessary for continued progress in cancer research. 
MicroRNAs (miRNAs) are endogenous small ncRNA molecules (19–22 bases in 
length) that regulate the expression of protein-coding genes by repressing 
translation or cleaving RNA transcripts in a sequence-specific manner.(5) Currently, 
2,578 human mature miRNAs are registered at miRBase release 20.0 
(http://microrna.sanger.ac.uk/). miRNAs are unique in their ability to regulate 
multiple protein-coding genes. Bioinformatic predictions indicate that miRNAs 
regulate >30-60% of the protein-coding genes in the human genome.(6,7)  
 A significant amount of evidence suggests that miRNAs are aberrantly 
expressed in many human cancers and that they play significant roles in the 
initiation, development and metastasis of those cancers.(8,9) Some highly expressed 
miRNAs can function as oncogenes by repressing tumor suppressors, whereas 
low-level miRNAs can function as tumor suppressors by negatively regulating 
oncogenes. It is believed that normal regulatory mechanisms can be disrupted by 
the aberrant expression of tumor-suppressive or oncogenic miRNAs in cancer cells. 
Therefore, identification of aberrantly expressed miRNAs is an important first step 
toward elucidating miRNA-mediated oncogenic pathways.  
Based on the foregoing, we have constructed miRNA expression signatures 
using PCa clinical specimens and investigated the roles of miRNAs in PCa 
oncogenesis using differentially expressed miRNAs.(10) Recently, we demonstrated 
that several miRNAs were downregulated in cancer tissues and that miR-1, 
miR-133a, miR-143 and miR-145 functioned as tumor suppressors by targeting 
several oncogenic genes.(11,12) Based on our PCa miRNA signature, miR-218 was 
significantly downregulated, suggesting that this miRNA might be a candidate 
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tumor suppressor in PCa cells. The aim of this study was to investigate the 
functional significance of miR-218 in cancer cells and to identify novel 
miR-218-regulated genes that contributed to PCa oncogenesis and metastasis. 
We found that restoration of mature miR-218 inhibited cancer cell migration 
and invasion, directly targeting LIM and SH3 protein 1 (LASP1). Downregulating 
the LASP1 significantly inhibited cell migration and invasion by cancer cells. 
Furthermore, LASP1-regulated novel molecular pathways were investigated 
through the use of si-LASP1-treated cells. Tumor-suppressive miR-218-LASP1 
mediated cancer pathways might provide new insights into the potential 
mechanisms of PCa oncogenesis and metastasis. 
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Materials and Methods 
Clinical prostate specimens 
Seventeen radical prostatectomy specimens were obtained from patients with 
PCa who underwent treatment at Chiba University Hospital (Chiba, Japan) from 
2009 to 2013. Seventeen paired samples of PCa and corresponding normal tissues 
were used for this study. The samples considered normal were free of cancer cells as 
determined by pathologic examination. The patients’ backgrounds and 
clinico-pathological characteristics are summarized in Table 1. Before tissue 
collection, all patients provided written informed consent of tissue donation for 
research purposes. The protocol was approved by the Institutional Review Board of 
Chiba University. 
 
Cell culture and RNA extraction 
PC3 and DU145 cells, human PCa cells obtained from the American Type 
Culture Collection (Manassas, VA, USA), were maintained in RPMI-1640 medium 
supplemented with 10% fetal bovine serum in a humidified atmosphere of 5% CO2 
and 95% air at 37°C. 
Total RNA was isolated from Formalin-Fixed Paraffin-Embedded (FFPE) 
sample with four 5µm thick slices, using the miRNeasy FFPE Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s protocol. RNA quality was confirmed 
using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). 
 
Quantitative real-time RT-PCR 
The procedure for PCR quantification was described as previously. (11-13) 
TaqMan probes and primers for LASP1 (P/N: Hs01078815_m1; Applied Biosystems, 
Foster City, CA, USA) and for GUSB (the internal control; P/N: Hs00939627_m1; 
Applied Biosystems) were assay-on-demand gene expression products. The 
expression levels of miR-218 (Assay ID: 000521; Applied Biosystems) were analyzed 
by TaqMan quantitative real-time PCR (TaqMan MicroRNA Assay; Applied 
Biosystems) and normalized to the expression of RNU48 (Assay ID: 001006; Applied 
Biosystems). All reactions were performed in triplicate, and each assay included 
negative control reactions that lacked cDNA. 
 
Transfections with mature miRNA and siRNA 
The following mature miRNA species were used in this study: mature miRNA, 
Pre-miRTM miRNA Precursor (has-miR-218; P/N: AM17100, Applied Biosystems). 
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The following siRNAs were used: Stealth Select RNAi siRNA, si-LASP1 (P/N: 
HSS105970; Invitrogen, Carlsbad, CA, USA), and negative control miRNA/siRNA 
(P/N: AM17111; Applied Biosystems). RNAs were incubated with OPTI-MEM 
(Invitrogen) and Lipofectamine RNAiMax reagent (Invitrogen) as described 
previously. The transfection efficiencies of miRNA in PC3 and DU145 cells were 
confirmed based on downregulation of TWF1 (PTK9) mRNA following transfection 
with miR-1 as previously reported.(13) 
 
Cell proliferation, migration, and invasion assays 
Cells were transfected with 10nM miRNA or siRNA by reverse transfection 
and plated in 96-well plates at 3 × 103 cells per well. After 72h, cell proliferation was 
determined with the XTT assay using a Cell Proliferation Kit II (Roche Molecular 
Biochemicals, Mannheim, Germany) as previously reported.(14,15) Cell migration was 
evaluated with a wound healing assay. Cells were plated in 6-well plates, and the 
cell monolayers were scraped using a P-20 micropipette tip. The initial gap length 
(0h) and the residual gap length 24h after wounding were calculated from 
photomicrographs.  
A cell invasion assay was carried out using modified Boyden chambers 
containing Transwell membrane filter inserts (precoated with Matrigel)  with 8µm 
pores in 24-well tissue culture plates (BD Biosciences, Bedford, MA, USA) at 2 × 105 
cells per well. Cells were transfected with 10nM miRNA or siRNA by reverse 
transfection and plated in 10cm dishes at 8 × 105 cells per dish. After 48h, the cells 
were collected, and 2 × 105 cells were added to the upper chamber of each migration 
well.     
Cells were allowed to invade for 48h. After gentle removal of the 
non-migratory cells from the filter surface of the upper chamber, the cells that 
invaded into the lower chamber were fixed and stained with Diff-Quick (Sysmex 
Corporation, Kobe, Japan). The number of cells that migrated to the lower surface 
was determined microscopically by counting four areas of constant size per well. All 
experiments were performed in triplicate. 
 
Western blotting 
Cells were harvested 72h after transfection, and lysates were prepared. 50µg 
protein lysates were separated on Mini-PROTEAN TGX gels (Bio-Rad, Hercules, 
CA, USA) and transferred to PVDF membranes. Immunoblotting was performed 
with mouse anti-LASP1 antibodies (1:250; HSA012072; Sigma-Aldrich, St.Louis, 
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MO, USA); anti-GAPDH antibodies (1:1000; ab8245, Abcam, Cambridge, UK) were 
used as an internal loading control.  
 
Screening of miR-218 and LASP1 target genes using in silico analysis and gene 
expression data 
Genes regulated by miR-218 were listed using the TargetScan database as 
described previously.(14,15) To investigate the expression status of candidate 
miR-218-target genes in PCa clinical specimens, we examined gene expression 
profiles in the the Gene Expression Omnibus (GEO) database (accession number: 
GSE29079). Also, we performed gene expression analysis using 
miR-218-transfected PC3 cells and si-LASP1-transfected PC3 cells compared to 
control transfection cells. Oligo-microarray Human 60K (Agilent) was used for gene 
expression studies. Microarray procedures and data mining methods were described 
previously. (14,15) 
 
Molecular pathway analysis using Kyoto Encyclopedia of Genes and Genomes 
pathways 
To identify molecular signaling pathways regulated by miR-218 or LASP1 in 
PCa cells, in silico and gene expression data were adapted to Kyoto Encyclopedia of 
Genes and Genomes (KEGG) pathways categories by the GENECODIS program 
(http://genecodis.dacya.ucm.es). The strategy of the analysis procedure was 
described previously.(12) 
 
Plasmid construction and dual-luciferase reporter assay 
Partial wild-type sequences of the LASP1 3’-untranslated region (UTR) or 
those with a deleted miR-218 target sites (positions 686-692, 1587-1593 and 
2080-2087 of the LASP1 3’-UTR) were inserted between the XhoI–PmeI restriction 
sites in the 3’-UTR of the hRluc gene in the psiCHECK-2 vector (C8021; Promega, 
Madison, WI, USA). The protocol for vector construction was described 
previously.(16) The synthesized DNA was cloned into the psiCHECK-2 vector. PC3 
cells were transfected with 50ng of the vector and 10nM miR-218 using 
Lipofectamine 2000 (Invitrogen). The activities of firefly and Renilla luciferases in 
cell lysates were determined with a dual-luciferase assay system (E1910; Promega). 
Normalized data were calculated as the ratio of Renilla/firefly luciferase activities. 
 
Immunohistochemistry 
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A total of 17 radical prostatectomy specimens were used (Table 1). Tissue 
specimens were immunostained following the manufacturer’s protocol with the 
UltraVision Detection System (Thermo Scientific, Fremont, CA, USA). Primary 
rabbit polyclonal antibodies against LASP1 (Sigma-Aldrich, St. Louis, MO) were 
diluted 1:500. The slides were treated with biotinylated goat antibodies. 
 
Statistical analysis 
The relationships between two groups and the numerical values obtained by 
real-time RT-PCR were analyzed using the paired t-test. The relationship among 
three variables and numerical values was analyzed using the Bonferroni-adjusted 
Mann-Whitney U test. All analyses were performed using Expert StatView software 
(version 4, SAS Institute Inc., Cary, NC, USA). 
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Results 
The expression levels of miR-218 in prostate cancer specimens and cell lines 
To validate our past miRNA profiling results, we evaluated the expression 
levels of miR-218 in 17 radical prostatectomy specimens. Quantitative stem-loop 
RT–PCR demonstrated that miR-218 expression was significantly lower in clinical 
PCa specimens and PCa cell lines (PC3 and DU145) compared with non-cancerous 
specimens (Fig. 1). The typical FFPE specimens that used for expression analysis in 
this study are shown in Fig. S1. 
 
Effects of restoring miR-218 on cell proliferation, migration and invasion activities 
in prostate cancer cell lines 
To investigate the functional effects of miR-218, we performed gain-of-function 
studies using miRNA transfection of PC3 and DU145 cell lines. 
The XTT assay demonstrated that cell proliferation was not inhibited in 
miR-218 transfectants in comparison with the mock or miR-control transfectant 
cells (Fig. 2A). 
The Matrigel invasion assay demonstrated that cell invasion activity was 
significantly inhibited in miR-218 transfectants in comparison with the mock or 
miR-control transfectant cells (Fig. 2B). 
The migration assay demonstrated that cell migration activity was 
significantly inhibited in miR-218 transfectants in comparison with the mock or 
miR-control transfectant cells (Fig. 2C). 
 
Identification of candidate genes targeted by miR-218 
To gain further insight into the genes affected by miR-218, we analyzed a 
combination of in silico and gene expression data from PCa clinical specimens. First, 
we screened miR-218-targeted genes using the TargetScan database and identified 
2,940 genes. Next, we pared down the 2,940 genes based on two kinds of gene 
expression data as follows: 1) upregulated genes determined by the gene expression 
data set of PCa clinical specimens in GEO (accession number: GSE29079), 2) 
downregulated genes (log2 ratio < -1.5) following miR-218 transfection of PC3 cells.  
In this selection, we narrowed down the miR-218 target genes for the analysis 
from 40 genes (table 2). Five genes (TPD52, ICK, ZHX3, LASP1 and VSIG10) were 
selected when we paid attention to the numbers of putative target sites of miR-218. 
Considering which genes are contributing to cancer cell migration and invasion 
among these five genes, we paid attention to cytoskeleton-regulated genes for 
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control of cancer metastasis according to our previous studies.(13,14) As a result of 
miR-218 target genes, we focused on the LIM and SH3 protein 1 (LASP1) gene, a 
cytoskeletal scaffold protein that has critical roles in cytoskeletal organization and 
cell migration. LASP1 was examined in further analyses.  
 
LASP1 was a direct target of miR-218 in prostate cells 
We performed quantitative real-time RT-PCR and Western blotting in PC3 and 
DU145 cells to investigate whether LASP1 gene expression and LASP1 protein 
expression were reduced by restoration of miR-218. The mRNA and protein 
expression levels of LASP1/LASP1 were significantly repressed in miR-218 
transfectants in comparison with mock or miR-control transfectants (Figs. 3A and 
3B). 
We performed luciferase reporter assays of PC3 to determine whether LASP1 
mRNA had target sites for miR-218. The TargetScan database predicted that three 
putative miR-218-binding sites existed in the 3’-UTR of LASP1 (positions 686-692, 
1587-1593 and 2080-2087, Fig. 3C). We used vectors encoding either the partial 
wild-type sequence of the 3’-UTR of LASP1 mRNA, including the predicted miR-218 
target sites, or ‘deletion’ vectors, that is, those lacking the miR-218 target sites. We 
found that the luminescence intensity was significantly reduced by transfection 
with miR-218 and two vectors carrying the wild-type 3’-UTR of LASP1 (positions 
686-692 and 1587-1593), whereas transfection with deletion vectors (where 
nucleotides at positions 695–691 and 2080-2086 had been removed) blocked the 
decrease in luminescence (P < 0.001, Fig. 3C). These data suggested that miR-218 
bounds directly to specific two binding sites in the 3’-UTR of LASP1 mRNA. 
 
Effects of downregulating LASP1 on cell proliferation, migration and invasion in 
prostate cancer cell lines 
To investigate the functional role of LASP1 in PCa cells, we performed 
loss-of-function studies using si-LASP1 transfectants. First, we evaluated the 
knockdown efficiency of si-LASP1 treatments in PC3 and DU145. Quantitative 
real-time RT-PCR and Western blotting indicated that the siRNA effectively 
downregulated LASP1/LASP1 expression in both cell lines (Fig. 4). 
The XTT assay demonstrated that cell proliferation was not inhibited in 
si-LASP1 transfectants in comparison with the mock or miR-control transfectant 
cells (Fig. 5A). The Matrigel invasion assay demonstrated that cell invasion activity 
was significantly inhibited in si-LASP1 transfectants in comparison with the mock 
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or negative control transfectant cells (Fig. 5B). The migration assay demonstrated 
that cell migration activity was significantly inhibited in si-LASP1 transfectants in 
comparison with the mock or negative control transfectant cells (Fig. 5C). 
 
Immunohistochemical detection of LASP1 in prostate cancer clinical specimens 
We determined the expression levels of LASP1 in PCa specimens by 
immunohistochemical staining. LASP1 was strongly expressed in several cancer 
lesions, whereas no or low expression was observed in normal regions (Fig. 6). There 
was no significant correlation between LASP1 expression and various tested 
clinicopathological parameters (Gleason score and stages, data not shown). 
 
Identification of novel molecular pathways regulated by LASP1 in prostate cancer 
cells 
To investigate molecular pathways regulated by LASP1, a genome-wide gene 
expression analysis was performed in PC3 cells. A total of 1,269 genes were 
downregulated in si-LASP1 transfection. Downregulated genes both 
si-LASP1-transfectants and miR-218-transfectans (top 18 genes) were shown in 
Table 3. We also assigned the down-regulated genes to KEGG pathways using the 
GeneCodis program (http://genecodis.cnb.csic.es) as described previously.(12,15) A 
total of 21 pathways were identified as significantly enriched annotations (Table 4). 
We focused on Focal adhesion pathway and the genes categorized in this pathway 
are listed in Table 5. 
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Discussion 
In early stage PCa, most patients initially respond to androgen deprivation 
therapy; however, many cases become refractory and progress to 
androgen-independent disease.(2) Currently, there is no effective treatment for 
hormone-refractory PCa, with disease progression and metastasis to the skeleton or 
other sites.(3) Thus, new approaches to effective treatments of hormone-refractory 
PCa are necessary. 
In cancer cells, aberrant expression of miRNAs can upset the tightly regulated 
system of miRNA-protein-coding RNA networks. Therefore, studies of differentially 
expressed miRNAs in cancer cells provide important information regarding the 
molecular mechanisms underlying oncogenesis and metastasis. To elucidate the 
molecular mechanisms underlying PCa, we have examined tumour-suppressive 
miRNAs, focusing on their regulated molecular targets and novel cancer pathways 
based on PCa expression signatures.(10) Our recent studies of miRNA expression 
signatures showed that miR-218 was frequently reduced in other types of cancer 
tissues and its functioned as a tumour suppressor.(17-19) Tumor-suppressive functions 
of miR-218 have been described by other research groups analyzing several types of 
cancers.(20-25) Thus, miR-218 is a key molecule in the development of human cancers, 
making it important to understand the cancer molecular network that miR-218 
regulates. The molecular mechanisms of miR-218 silencing in PCa cells are still 
unclear. Human genome database indicates that miR-218 is located two different 
human chromosome loci (miR-218-1 at 4p15.31 and miR-218-2 at 5q35.1) and these 
miRNAs are embedded in the intronic regions of SLIT2 and SLIT3, respectively. 
Previous reports showed that expression of SLIT2 and SLIT3 were downregulated 
in several types of cancer cells through their promoter hypermethylation.(20,24) Our 
preliminary examination showed that downregulation of the SLIT2 and SLIT3 were 
observed in primary PCa tissues (Fig. S2). Furthermore, re-expression of SLIT2 and 
miR-218 were observed after 5-aza-2’-deoxycytidine treatment of PCa cell line (Fig. 
S3). Thus, our data and previous studies provided that promoter hypermethylation 
of SLIT2 and SLIT3 regions drove PCa progression and derived downregulation of 
miR-218 in PCa cells. 
To better understand PCa metastasis, we identified miR-218 target genes 
using in silico analysis. As determined by our laboratory and others, the targets of 
miR-218 include CAV1, LAMB3, ECOP, IKK-B, PXN, RICTOR, BIRC5 and 
ROBO1.(17,18,20,22-25) Here, we focused on LASP1, a cytoskeletal scaffold protein. It 
plays critical roles in cytoskeletal organization and cell migration. LASP1 was 
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initially identified in a cDNA library constructed from metastasized breast cancer 
cells. LASP1 encodes a LIM motif at its N-terminus and a src homology 3 (SH3) 
domain at its C-terminus.(26,27) The C-terminal SH3 domain of LASP1 functions in 
protein-protein interactions such as vasodilator-stimulated phosphoprotein (VASP), 
palladin and zyxin.(28-30)  Zyxin might function as a messenger in the signal 
transduction pathway that mediates adhesion-stimulated changes in gene 
expression and might also modulate the cytoskeletal organization of actin 
bundles.(30-32) In this study, we performed genome-wide gene expression analysis 
using si-LASP1 transfectant PC3 cells to investigate LASP1-regulated molecular 
targets and pathways. Our data showed that zyxin was downregulated in 
LASP1-suppressed cells.  Zyxin is reportedly regulated by TGF-β and contributes 
to the epithelial-mesenchymal transition.(31,32) Therefore, it will be important to 
analyze the molecular mechanisms of LASP1-zyxin signal transduction to better 
understand the metastasis of human cancer cells. 
Overexpression of LASP1 has been reported in metastatic breast and 
ovarian cancers.(33,34) Our group showed that LASP1 gene expression was elevated 
in bladder cancer and that downregulation of the LASP1 gene inhibited cancer cell 
migration and invasion(16), suggesting that LASP1 significantly contributes to 
cancer metastasis. This is the first report to show that overexpression of LASP1 in 
PCa clinical tissues might be involved in the metastasis of PCa. Our previous 
analysis of bladder cancer showed tumor-suppressive miRNAs such as miR-1, 
miR-133a and miR-218 regulated LASP1.(16)  Recent studies demonstrated that 
LASP1 was regulated by miR-203 in in breast cancer and esophageal cancer.(35-37) 
Immunohistchemical staining demonstrated that the overexpression of LASP1 was 
detected in primary PCa tissues compared with non-PCa tissues. We also measured 
the expression of miR-218 status using the same FFPE tissues whether the 
downregulation of miR-218 was associated with upregulation of LASP1 in PCa. Our 
data showed that expression of miR-218 was significantly reduced in LASP1 
overexpression PCa tissues in comparison to LASP1 low staining of non-PCa tissues 
(Fig. S4). Our data of primary PCa tissues and cell lines might be suggesting that 
downregulation of miR-218 caused to upregulation of LASP1 in PCa cells. Improved 
understanding of tumour-suppressive miRNAs and their regulation of LASP1 
signalling should shed light on PCa metastasis as well as delineate more effective 
strategies for future therapeutic interventions for this disease. 
In conclusion, miR-218 was significantly downregulated in PCa clinical 
specimens and appeared to function as a tumor suppressor through regulation of 
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oncogenic LASP1. Elucidation of the cancer pathways and target genes regulated by 
the tumor-suppressive miR-218 should provide new information on potential 
therapeutic targets in the treatment of PCa metastasis. 
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Figure Legends 
Figure 1 
The expression levels of miR-218 in clinical specimens and PCa cell lines (PC3 and 
DU145).  
Real-time PCR showed that the expression levels of miR-218 were significantly 
lower in PCa tissues and cell lines than in normal prostate tissues. RNU48 was 
used as an internal control. 
 
Figure 2 
Effects of miR-218 transfection on prostate cancer (PCa) cell lines (PC3 and 
DU145). 
(A) Cell proliferation was determined with XTT assays 72 h after transfection with 
ten nM miR-218, miR-control, or mock transfection. (B) Cell invasion activity was 
determined with the Matrigel invasion assay. (C) Cell migration activity determined 
with the wound healing assay. *P < 0.001.  
 
Figure 3 
LASP1 expression was suppressed by miR-218 transfection of prostate cancer (PCa) 
cells lines. 
(A) LASP1 mRNA expression 72 h after transfection with miR-218. GUSB 
expression was used for normalization. (B) LASP1 protein expression 72 h after 
transfection with miR-218. GAPDH was used as a loading control. (C) miR-218 
binding sites in the 3’-UTR of LASP1 mRNA. Luciferase reporter assays using three 
vectors encoding putative miR-218 target sites at positions 686-692, 1587-1593 and 
2080-2087 for both wild-type (WT) and deletion (DEL). Renilla luciferase values 
were normalized to firefly luciferase values. *P < 0.001. 
 
Figure 4 
LASP1 mRNA and LASP1 protein expression levels were suppressed by si-LASP1 
transfection of DU145 and PC3 cells. 
 (A) LASP1 mRNA expression 72h after transfection with si-LASP1. GUSB 
expression was used for normalization. (B) LASP1 protein expression 72h after 
transfection with si-LASP1. GAPDH was used as a loading control. The ratio of 
LASP1/GAPDH expression was evaluated using ImageJ software (ver. 1,43; 
http://rsbweb.nih.gov/ij/index.htmL). 
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Figure 5 
Effects of LASP1 downregulation by si-LASP1 on prostate cancer (PCa) cells (PC3 
and DU145). 
(A) Cell proliferation determined with the XTT assay. (B) Cell migration activity 
determined with the wound healing assay. (C) Cell invasion activity determined 
with the Matrigel invasion assay. *P < 0.001. 
 
Figure 6 
Immunohistochemical staining of LASP1 in prostate clinical specimens. 
Differences in LASP1 expression were observed in cancer lesions and adjacent 
normal prostate tissues in the same fields (A: Patient number 6, B: patient number 
16). Overexpression of LASP1 was observed in cancer lesions. In contrast, negative 
staining of LASP1 in normal prostate glands and stromal tissues (left panel, 
original magnification X50; right panel, original magnification X100). 
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Supporting information 
Supplemental Figure 1 
H&E staining of the formalin-foxed paraffin-embedded (FFPE) prostate specimens. 
 
Supplemental Figure 2 
Expression levels of SLIT2, SLIT3 and miR-218 in prostate cancer (PCa) tissues. 
 
Supplemental Figure 3 
Effects of 5-aza-2’-deoxycytidine (5-aza-dc) treatment of prostate cancer (PCa) cells. 
 
Supplemental Figure 4 
Expression levels of miR-218 in prostate cancer (PCa) tissues. 
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Table1
Patients’ characteristics
No.
PCa or
non-PCa
Age
PSA
(ng/ml)
Gleason score Stage T N M
1 PCa 64 5.4 3+4 C 3a 0 0
2 PCa 68 12.8 3+5 C 3a 0 0
3 PCa 70 16.1 4+5 C 3b 0 0
4 PCa 69 25.8 4+5 B 2a 0 0
5 PCa 64 29.9 4+3 B 2b 0 0
6 PCa 61 7.9 3+4 C 3a 0 0
7 PCa 68 8.8 4+5 B 2b 0 0
8 PCa 66 6.1 4+3 B 2b 0 0
9 PCa 70 11.8 4+4 C 3b 0 0
10 PCa 60 22.1 3+4 B 2b 0 0
11 PCa 70 8.9 3+4 B 2a 0 0
12 PCa 72 4.5 3+4 B 2b 0 0
13 PCa 56 7.1 3+4 C 3a 0 0
14 PCa 65 13.1 4+3 B 2b 0 0
15 PCa 65 9.5 4+4 B 2b 0 0
16 PCa 65 5.8 4+3 B 2a 0 0
17 PCa 65 4.6 5+4 B 2b 0 0
1 non-PCa
2 non-PCa
3 non-PCa
4 non-PCa
5 non-PCa
6 non-PCa
7 non-PCa
8 non-PCa
9 non-PCa
10 non-PCa
11 non-PCa
12 non-PCa
13 non-PCa
14 non-PCa
15 non-PCa
16 non-PCa
17 non-PCa
TNM
classification
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Table 2
Candidate of putative miR-218  target genes
Entrez
gene ID
Symbol Gene name Location Fold change
miR-218
transfectant
conserved
sites
poorly
conserved
sites
 5652 PRSS8 protease, serine, 8 16p11.2 1.58 -2.08 0 1
7163 TPD52 tumor protein D52  8q21 1.52 -2.22 2 1
 5591 PRKDC protein kinase, DNA-activated, catalytic polypeptide 8q11 1.43 -1.88 0 2
22858 ICK intestinal cell (MAK-like) kinase 6p12.1 1.41 -2.28 2 1
10983 CCNI cyclin I 4q21.1 1.39 -1.56 0 1
 8871 SYNJ2 synaptojanin 2 6q25.3 1.39 -1.77 0 1
5054 SERPINE1 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 7q22.1 1.38 -2.56 0 1
23051 ZHX3 zinc fingers and homeoboxes 3 20q12 1.33 -1.74 0 3
85414 SLC45A3 solute carrier family 45, member 3 1q32.1 1.32 -1.50 1 0
80195 TMEM25 transmembrane protein 254 10q22.3 1.31 -2.01 1 0
9342 SNAP29 synaptosomal-associated protein, 29kDa 22q11.21 1.30 -1.91 0 1
9289 GPR56 G protein-coupled receptor 56 16q13 1.30 -2.23 0 1
6745 SSR1 signal sequence receptor, alpha  6p24.3 1.30 -1.63 1 0
3927 LASP1 LIM and SH3 protein 1 17q11-q21.3 1.28 -1.96 1 2
54443 ANLN anillin, actin binding protein  7p15-p14 1.26 -1.82 0 1
1824 DSC2 desmocollin 2 18q12.1 1.25 -2.33 0 1
10447 FAM3C family with sequence similarity 3, member C 7q31 1.24 -1.92 1 0
79443 FYCO1 FYVE and coiled-coil domain containing 1 3p21.31 1.24 -1.62 1 0
4008 LMO7 LIM domain 7 13q22.2 1.22 -1.75 1 0
272 AMPD3 adenosine monophosphate deaminase 3 11p15 1.22 -1.57 0 1
9725 TMEM63A transmembrane protein 63A 1q42.12 1.21 -1.64 0 1
9917 FAM20B family with sequence similarity 20, member B 1q25 1.21 -1.63 1 1
114908 TMEM123 transmembrane protein 123 11q22.1 1.19 -1.69 1 0
5781 PTPN11 protein tyrosine phosphatase, non-receptor type 11 12q24 1.17 -1.50 1 0
5175 PECAM1 platelet/endothelial cell adhesion molecule 1 17q23.3 1.16 -1.89 0 2
23788 MTCH2 mitochondrial carrier 2 11p11.2 1.16 -2.28 0 2
79071 ELOVL6 ELOVL fatty acid elongase 6 4q25 1.15 -2.30 0 1
6645 SNTB2 syntrophin, beta 2 (dystrophin-associated protein A1, 59kDa, basic component 2) 16q22.1 1.15 -2.34 1 1
10613 ERLIN1 ER lipid raft associated 1 10q24.31 1.14 -1.62 0 1
112939 NACC1 nucleus accumbens associated 1, BEN and BTB (POZ) domain containing 19p13.2 1.14 -1.63 2 0
54902 TTC19 tetratricopeptide repeat domain 19 17p12 1.14 -1.74 0 1
55604 LRRC16A leucine rich repeat containing 16A 6p22.2 1.13 -2.29 0 1
26420 MAPK9 mitogen-activated protein kinase 9 11 1.13 -1.51 0 1
9497 SLC4A7 solute carrier family 4, sodium bicarbonate cotransporter, member 7  3p22 1.12 -1.95 0 1
10186 LHFP lipoma HMGIC fusion partner 13q12 1.12 -1.79 2 0
 66008 TRAK2 trafficking protein, kinesin binding 2 2q33 1.10 -1.67 0 1
54621 VSIG10 V-set and immunoglobulin domain containing 10 12q24.23 1.09 -2.06 1 2
357 SHROOM2 shroom family member 2 Xp22.3 1.08 -1.78 0 2
41 ACCN2 acid-sensing (proton-gated) ion channel 1 12q12 1.08 -1.51 1 0
3248 HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) 4q34-q35 1.02 -2.54 1 1  
 
Table 3
Downregulated genes both si-LASP1 and miR-218- transfects in PC3 cells
Entrez Gene
ID
 Symbol  Gene Name
miR-218
transfectant
siLASP1
transfectant
10529 NEBL nebulette -2.03 -3.79
54757 FAM20A family with sequence similarity 20, member A -2.09 -2.93
3131 HLF hepatic leukemia factor -4.69 -2.62
1381 CRABP1 cellular retinoic acid binding protein 1 -1.33 -2.60
254552 NUDT8 nudix (nucleoside diphosphate linked moiety X)-type motif 8 -2.57 -2.53
4312 MMP1 matrix metallopeptidase 1 (interstitial collagenase) -0.90 -2.53
3927 LASP1 LIM and SH3 protein 1 -1.96 -2.50
27151 CPAMD8 C3 and PZP-like, alpha-2-macroglobulin domain containing 8 -0.56 -2.49
3866 KRT15 keratin 15 -3.32 -2.44
126823 KLHDC9 kelch domain containing 9 -0.99 -2.43
8722 CTSF cathepsin F -0.84 -2.43
128434 VSTM2L V-set and transmembrane domain containing 2 like 0.00 -2.35
3339 HSPG2 heparan sulfate proteoglycan 2 -2.23 -2.28
 6678 SPARC secreted protein, acidic, cysteine-rich (osteonectin) -4.21 -2.24
10669 CGREF1 cell growth regulator with EF-hand domain 1 -0.78 -2.13
25890 ABI3BP ABI family, member 3 (NESH) binding protein -2.58 -2.12
11093 ADAMTS13 ADAM metallopeptidase with thrombospondin type 1 motif, 13 -0.67 -2.10
2171 FABP5 fatty acid binding protein 5 (psoriasis-associated) -1.58 -2.09
Expression (log2 ratio)
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Table 4
Significantly enriched KEGG pathways regulated by si-LASP 1 in PC3 cells
Number of
genes
P  value Annotations
17 8E-08 (KEGG) 04512: ECM-receptor interaction 
16 6.7E-05 (KEGG) 04142: Lysosome 
18 0.00013 (KEGG) 05010: Alzheimer's disease 
15 0.00054 (KEGG) 04910: Insulin signaling pathway 
11 0.00062 (KEGG) 04146: Peroxisome 
16 0.00079 (KEGG) 04141: Protein processing in endoplasmic reticulum 
18 0.0008 (KEGG) 04510: Focal adhesion 
8 0.00105 (KEGG) 00280: Valine, leucine and isoleucine degradation 
15 0.00184 (KEGG) 00230: Purine metabolism 
9 0.00462 (KEGG) 03320: PPAR signaling pathway 
15 0.00537 (KEGG) 05016: Huntington's disease 
22 0.00548 (KEGG) 05200: Pathways in cancer 
6 0.00593 (KEGG) 00640: Propanoate metabolism 
10 0.01371 (KEGG) 05146: Amoebiasis 
6 0.02207 (KEGG) 00480: Glutathione metabolism 
11 0.02289 (KEGG) 00190: Oxidative phosphorylation 
11 0.02296 (KEGG) 05012: Parkinson's disease 
13 0.02655 (KEGG) 04020: Calcium signaling pathway 
8 0.03817 (KEGG) 05222: Small cell lung cancer 
8 0.04822 (KEGG) 05322: Systemic lupus erythematosus 
8 0.04917 (KEGG) 05414: Dilated cardiomyopathy  
 
 
Table 5
Downregulated genes involved in Focal adhesion pathway by si-LASP1  transfectant in PC3 cells
 Entrez Gene
ID
 Gene symbol  Gene name
miR-218
transfectant
siLASP1
transfectant
7791 ZYX zyxin -0.64 -0.51
1288 COL4A6 collagen, type IV, alpha 6 -0.9 -0.86
3913 LAMB2 laminin, beta 2 (laminin S) -0.53 -0.85
2064 ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) -0.63 -0.91
3675 ITGA3 integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) -0.7 -0.79
1287 COL4A5 collagen, type IV, alpha 5 -0.45 -0.7
7148 TNXB tenascin XB -1.18 -1.71
1290 COL5A2 collagen, type V, alpha 2 1.57 -0.82
25759 SHC2 SHC (Src homology 2 domain containing) transforming protein 2 0.72 -0.85
207 AKT1 v-akt murine thymoma viral oncogene homolog 1 -0.52 -0.53
3910 LAMA4 laminin, alpha 4 0.49 -1.07
5881 RAC3 ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3) -0.07 -0.58
1292 COL6A2 collagen, type VI, alpha 2 0.19 -1.3
1289 COL5A1 collagen, type V, alpha 1 1.34 -0.84
3691 ITGB4 integrin, beta 4 -0.82 -1.17
3912 LAMB1 laminin, beta 1 0.2 -0.58
7059 THBS3 thrombospondin 3 -1.2 -1.09
5500 PPP1CB protein phosphatase 1, catalytic subunit, beta isozyme -2.1 -0.5
Expression (log2 ratio)
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